Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) EPH Receptor A3 Antibodies:
anti-Human EPH Receptor A3 Antibodies:
anti-Rat (Rattus) EPH Receptor A3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal EPH Receptor A3 Primary Antibody for RNAi, ELISA - ABIN560754
Peng, Wang, Liu, Ye, Wu, Guo: EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway. in Tumour biology 2016
Human Monoclonal EPH Receptor A3 Primary Antibody for ELISA, WB - ABIN969101
Ota, Suzuki, Nishikawa, Otsuki, Sugiyama, Irie, Wakamatsu, Hayashi, Sato, Nagai, Kimura, Makita, Sekine, Obayashi, Nishi, Shibahara, Tanaka, Ishii, Yamamoto, Saito, Kawai, Isono, Nakamura, Nagahari et al.: Complete sequencing and characterization of 21,243 full-length human cDNAs. ... in Nature genetics 2003
Show all 2 Pubmed References
EPHA6, a gene implicated in retinal axon guidance, is one of HMX1 targets in eye development.
study delineates a mechanism in which NCAM (show NCAM1 Antibodies) promotes ephrin-A5 (show EFNA5 Antibodies)-dependent clustering of EphA3 through interaction of the NCAM (show NCAM1 Antibodies) Ig2 domain and the EphA3 CRD (show CRX Antibodies), stimulating EphA3 autophosphorylation and RhoA (show RHOA Antibodies) signaling necessary for growth cone repulsion in GABAergic interneurons in vitro, which may extend to remodeling of axonal terminals of interneurons in vivo.
Ephrin-A3 (show EFNA3 Antibodies) has a role in promoting and maintaining slow muscle fiber identity during postnatal development and reinnervation
the physiological role of the putative lung cancer tumor suppressor EPH receptor A3, is reported.
ephrinA5/EphA3 triggers proteolysis of the neural cell adhesion molecule (NCAM (show NCAM1 Antibodies)) by the metalloprotease (show ADAMTS7 Antibodies) a disintegrin and metalloprotease (ADAM)10 (show ADAM10 Antibodies) to promote growth cone collapse in neurons from mouse neocortex.
EphA3 receptor localized only in neuronal cells of the hippocampus was enhanced without transcriptional regulation during synaptic plasticity through activation of the nicotinic acetylcholine receptor.
Data show that a number of Eph (show EPHA1 Antibodies) receptors and ephrins were expressed in hematopoietic stem cells.
Neocortical expression of Epha3 during development remains stable in the absence of cellular contacts and thalamocortical connections.
Retrograde labeling studies in EphA3(-/-) embryos and adults indicate that EphA3 is not necessary to direct motor axons to axial muscle targets.
A discrepancy between mRNA and protein expression was found between early and later developmental stages, suggesting that EphA3 might regulate the formation of various neuronal networks in the developing brain.
results indicate that EphA3 plays a crucial role in the development and morphogenesis of the cells that give rise to the atrioventricular valves and septa (show SEPT2 Antibodies).
Results indicate that EphA3 protein expression is reduced in clear-cell renal cell carcinoma (show MOK Antibodies), suggesting the possibility that this receptor functions as a tumor suppressor in this disease.
EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic signaling pathways.
Data indicate that EPHA3 is involved in regulating the multidrug resistance (MDR) of small cell lung cancer (SCLC) via PI3K (show PIK3CA Antibodies)/BMX (show BMX Antibodies)/STAT3 (show STAT3 Antibodies) signaling and may be a therapeutic target in SCLC.
PTP-PEST (show PTPN12 Antibodies) regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP (show SLC25A3 Antibodies) controlling EphA3 phosphorylation.
This study showed that EPHA3 gene involved in neuronal growth and cerebellum development and associated with neurological and psychological disorders.
A novel association between the EPHA3 deletion and prostate cancer risk was observed in Finnish individuals.
the structure of the ligand-binding domain of the EphA3 receptor in complex with its preferred ligand, ephrin-A5 (show EFNA5 Antibodies), is reported.
EphA3 forms dimers in the absence of ligand binding.
Data indicate that hypoxia increased EphA3 receptor (EphA3) mRNA expression in EphA3+ endometrial multipotent mesenchymal stromal cells (eMSCs).
EphA3 was induced by PC-1 (show PCSK1 Antibodies) and contributed to the malignant progression of prostate cancer
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Two alternatively spliced transcript variants have been described for this gene.
eph-like receptor tyrosine kinase 2
, ephrin receptor EphA3
, EPH receptor A3
, ephrin type-A receptor 3-like
, EPH-like kinase 4
, ephrin type-A receptor 3
, tyrosine-protein kinase TYRO4
, tyrosine-protein kinase receptor ETK1
, TYRO4 protein tyrosine kinase
, eph-like tyrosine kinase 1
, human embryo kinase 1
, tyrosine-protein kinase receptor REK4
, receptor tyrosine kinase
, eph-like receptor tyrosine kinase 7
, tyrosine-protein kinase receptor ZEK1